“SGLT2 Inhibitors More Effective than DPP4 Inhibitors for Fatty Liver Improvement in Metabolic Dysfunction and Diabetes Patients”

https://pubmed.ncbi.nlm.nih.gov/38114769

This study found that, in patients with both metabolic dysfunction-associated fatty liver disease and diabetes mellitus, use of sodium-glucose cotransporter 2 inhibitors was associated with greater improvement in fatty liver index compared to dipeptidyl peptidase 4 inhibitors.